. Author manuscript; available in PMC: 2016 Jul 14.

Published in final edited form as: J Med Chem. 2015 Feb 20;58(5):2206–2220. doi: 10.1021/jm501518y

Table 4.

Antiproliferative effect of selected compounds against MDR cells and patient-derived GBM neurosphere cells

compound	GI₅₀ in vitro values (μM)
compound	MES-SA^a	MES-SA/Dx5^a	GBM 031810^b

Taxol	0.007 ± 0.001	9.8 ± 0.3
Vinblastine	0.006 ± 0.001	5.0 ± 1.4
Temozolomide			> 1000
3aafa	2.0 ± 0.2	4.0 ± 1.1	0.8 ± 0.6
3aafp	0.8 ± 0.1	1.6 ± 0.6	5.6 ± 0.8
3aafe	1.7 ± 0.4	4.9 ± 1.9	3.4 ± 0.7
3aafk	1.8 ± 0.4	2.2 ± 0.8
3cafa	5.9 ± 1.7	2.7 ± 0.3
3eafa	7.1 ± 0.1	8.5 ± 0.9

Concentration required to reduce the viability of cells by 50% after a 48 h treatment with the indicated compounds relative to a DMSO control ± SD from two independent experiments, each performed in 4 replicates, as determined by the MTT assay.

Average GI₅₀ ± SD from three GI₅₀ determinations.